114 related articles for article (PubMed ID: 34077013)
21. Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway.
Wei B; Wang Y; Wang J; Cai X; Xu L; Wu J; Wang Y; Liu W; Gu Y; Guo W; Xu Q
Cancer Cell Int; 2020; 20():198. PubMed ID: 32514243
[TBL] [Abstract][Full Text] [Related]
22. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
[TBL] [Abstract][Full Text] [Related]
24. Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2.
Yang X; Li W; Han X; Wang J; Dai J; Ye X; Meng M
Sci Rep; 2024 Jan; 14(1):879. PubMed ID: 38195651
[TBL] [Abstract][Full Text] [Related]
25. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
27. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
28. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.
Lin Y; Zhai E; Liao B; Xu L; Zhang X; Peng S; He Y; Cai S; Zeng Z; Chen M
Oncotarget; 2017 Feb; 8(7):11990-12002. PubMed ID: 28061477
[TBL] [Abstract][Full Text] [Related]
29. MRI analysis of hydrogel-loaded apatinib for local therapy of hepatocellular carcinoma model in nude mice.
Liu Z; Wang C; Wu G; Cheng J
Biochem Biophys Res Commun; 2019 Feb; 509(2):529-534. PubMed ID: 30598262
[TBL] [Abstract][Full Text] [Related]
30. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
[TBL] [Abstract][Full Text] [Related]
31. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
[TBL] [Abstract][Full Text] [Related]
32. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
Chen S; Yao L
Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
[TBL] [Abstract][Full Text] [Related]
33. Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells.
Hu C; Zhu P; Xia Y; Hui K; Wang M; Jiang X
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1329-1337. PubMed ID: 29777301
[TBL] [Abstract][Full Text] [Related]
34. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
Li B; Yang J; Lu Z; Liu B; Liu F
J BUON; 2019; 24(2):739-745. PubMed ID: 31128031
[TBL] [Abstract][Full Text] [Related]
35. Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway.
Xia L; Gong M; Zou Y; Wang Z; Wu B; Zhang S; Li L; Jin K; Sun C
Oxid Med Cell Longev; 2022; 2022():9925919. PubMed ID: 35602105
[TBL] [Abstract][Full Text] [Related]
36. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
37. Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway.
Xie Q; Wang J; Wu W; Zhao Y
Am J Transl Res; 2022; 14(1):421-431. PubMed ID: 35173861
[TBL] [Abstract][Full Text] [Related]
38. Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway.
Wu J; Yu J; Wang J; Zhang C; Shang K; Yao X; Cao B
Biomed Pharmacother; 2018 Apr; 100():176-183. PubMed ID: 29428665
[TBL] [Abstract][Full Text] [Related]
39. Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway.
Jia X; Wen Z; Sun Q; Zhao X; Yang H; Shi X; Xin T
J BUON; 2019; 24(5):1985-1991. PubMed ID: 31786865
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
